TG Therapeutics is entering the neurology market with their approved multiple sclerosis drug, Briumvi, challenging competitors like Roche. Click here to know more.

Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREV…

Biogen (BIIB) on Friday said the U.S. FDA had approved its biosimilar to Roche''s (RHHBY) (RHHBF) arthritis treatment Actemra (tocilizumab). Read more here.

Biogen Inc. BIIB said late Friday the Food and Drug Administration approved its biosimilar version of Roche CH:ROG‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, or tocilizumab-bavi, is the first FDA-approved biosimilar to tocilizumab, which Roche brands as Actemra. Biogen’s approval covers marketing for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, the company said. Biosimilars are to branded biologics the way generic drugs are to branded drugs except the FDA regulates the two classes in different ways. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Nintendo -0.19% ThuringiaInvest (THURINT): Dividendenzahlung von 13,77 Euro. (28.09. 08:29) >> mehr comments zu Nintendo: www.boerse-social.com/launch/aktie/nintendo Netflix -0.03% TennoForcystus (…

Ionis Pharmaceuticals Inc (NASDAQ: IONS ) entered an agreement with Roche Holdings AG (OTC: RHHBY ) for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer''s disease (AD) and Huntington''s disease (HD) . Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization. Under the terms of the agreement, Ionis will be responsible for advancing the two programs through pre-clinical studies; Roche will have sole responsibility for clinical development and, if approved, commercialization worldwide. Ionis will receive a … Full story available on Benzinga.com

Roche acquires global license from Ionis Pharmaceuticals for RNA-targeted drug candidates in Alzheimer''s and Huntington''s diseases. Read more here.

Futures Rebound After Tuesday Rout As Rates Drop After Tuesday''s sharp rout, US equity futures are higher despite another slump in Asian markets and mixed European bourses, potentially setting up a relief rally as yields are lower with 10Y under 4.50% even as investors keep a close eye on the risk of a government shutdown and the Dollar keeps rising to the point where another Plaza Accord may be required. As of 7:45am ET, S&P futures were 0.4% higher while Nasdaq futures rose 0.3%; on Tuesday the DJIA fell below its 200-day moving average, a technical signal that suggests the index has become oversold while the VIX retreated after hitting its highest level since May. Commodities are mostly higher with WTI back above $91, leading Energy. Today''s macro data focus is on durable goods and the 5Y Treasury auction ($49bn). Tomorrow we resume with Fed speakers and Friday’s PCE/Consumption data are the most impactful data points of the week. In premarket trading, Costco fell 2% despite beating earnings estimates.

The health authorities in Punjab province had launched the investigation into local use of the drug Avastin

… medication distributed by Swiss pharmaceutical company Roche pending an investigation, as … said. Repeated calls to Roche Pakistan''s spokesman … answered. On its website, Roche said Avastin was approved … has inflated the price of drugs in Pakistan, as the …